Kairos Pharma, Stock Performance
| KAPA Stock | 0.74 0.01 1.33% |
The company secures a Beta (Market Risk) of 3.29, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Kairos Pharma, will likely underperform. At this point, Kairos Pharma, has a negative expected return of -0.47%. Please make sure to verify Kairos Pharma,'s total risk alpha, accumulation distribution, period momentum indicator, as well as the relationship between the potential upside and day median price , to decide if Kairos Pharma, performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Kairos Pharma, has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Can Kairos Pharma Ltd. stock rebound after recent weakness - Weekly Gains Report Reliable Volume Spike Trade Alerts - newser.com | 10/24/2025 |
2 | Why Kairos Pharma Ltd. stock attracts global investors - Portfolio Growth Summary Stock Timing and Entry Methods - newser.com | 10/29/2025 |
3 | Is Kairos Pharma Ltd. stock safe for risk averse investors - Gap Down Stock Portfolio Risk Management - fcp.pa.gov.br | 11/05/2025 |
4 | Will Kairos Pharma Ltd. stock benefit from infrastructure bill - 2025 Technical Overview Community Consensus Picks - newser.com | 11/12/2025 |
5 | Why Kairos Pharma Ltd. stock stays resilient - Quarterly Profit Report Reliable Trade Execution Plans - newser.com | 11/19/2025 |
6 | Is Kairos Pharma Ltd. stock positioned for digital transformation - Trade Risk Report AI Enhanced Trade Execution Alerts - Newser | 12/04/2025 |
Kairos Pharma, Relative Risk vs. Return Landscape
If you would invest 110.00 in Kairos Pharma, on September 26, 2025 and sell it today you would lose (36.00) from holding Kairos Pharma, or give up 32.73% of portfolio value over 90 days. Kairos Pharma, is currently does not generate positive expected returns and assumes 5.7031% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Kairos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kairos Pharma, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kairos Pharma,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kairos Pharma,, and traders can use it to determine the average amount a Kairos Pharma,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0818
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KAPA |
Based on monthly moving average Kairos Pharma, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kairos Pharma, by adding Kairos Pharma, to a well-diversified portfolio.
Kairos Pharma, Fundamentals Growth
Kairos Stock prices reflect investors' perceptions of the future prospects and financial health of Kairos Pharma,, and Kairos Pharma, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kairos Stock performance.
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 12.58 M | ||||
| Shares Outstanding | 20.82 M | ||||
| Price To Book | 2.04 X | ||||
| EBITDA | (1.58 M) | ||||
| Net Income | (2.6 M) | ||||
| Total Debt | 1.44 M | ||||
| Book Value Per Share | 0.37 X | ||||
| Cash Flow From Operations | (3.96 M) | ||||
| Earnings Per Share | (0.31) X | ||||
| Market Capitalization | 15.66 M | ||||
| Total Asset | 6.22 M | ||||
| Retained Earnings | (8.81 M) | ||||
| Working Capital | 3.18 M | ||||
About Kairos Pharma, Performance
By analyzing Kairos Pharma,'s fundamental ratios, stakeholders can gain valuable insights into Kairos Pharma,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Kairos Pharma, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kairos Pharma, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.47) | (0.49) | |
| Return On Capital Employed | (0.49) | (0.47) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (0.55) | (0.52) |
Things to note about Kairos Pharma, performance evaluation
Checking the ongoing alerts about Kairos Pharma, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kairos Pharma, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kairos Pharma, generated a negative expected return over the last 90 days | |
| Kairos Pharma, has high historical volatility and very poor performance | |
| Kairos Pharma, has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (2.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kairos Pharma, generates negative cash flow from operations | |
| Kairos Pharma, has a frail financial position based on the latest SEC disclosures | |
| About 41.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Is Kairos Pharma Ltd. stock positioned for digital transformation - Trade Risk Report AI Enhanced Trade Execution Alerts - Newser |
- Analyzing Kairos Pharma,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kairos Pharma,'s stock is overvalued or undervalued compared to its peers.
- Examining Kairos Pharma,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kairos Pharma,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kairos Pharma,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kairos Pharma,'s stock. These opinions can provide insight into Kairos Pharma,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Kairos Stock analysis
When running Kairos Pharma,'s price analysis, check to measure Kairos Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kairos Pharma, is operating at the current time. Most of Kairos Pharma,'s value examination focuses on studying past and present price action to predict the probability of Kairos Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kairos Pharma,'s price. Additionally, you may evaluate how the addition of Kairos Pharma, to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |